Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
ODDITY TECH 0CDI.PA-O 0META 11.03MNT.TO 0.69COPX 1.79U.U.TO 0.5SII.TO 2.94IPCO.TO -0.43
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

28.57
+0.60 (2.15%)
as of Aug 25, 2026, 8:00:00 pm Market Open.
582 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 25, 2026, 12:00 am

This summary was created by AI, based on 24 opinions in the last 12 months.

Pfizer Inc. (PFE) has faced challenges following its prominent role during the Covid-19 pandemic, with many experts pointing out the looming patent cliffs and the need for new blockbuster drugs to sustain growth. The company is heavily reliant on its dividends, offering yields between 6% to 8%, which many investors find attractive in a low growth environment. While some view it as a value play due to its low price-to-earnings ratio, others express concerns that it may be a value trap due to uncertain growth prospects. The overall sentiment reflects a cautious approach, favoring the dividend payout amidst worries about drug pipeline sustainability and the impact of recent acquisitions on its future performance.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
DON'T BUY

Pfizer Inc(PFE)

Feb 13, 2009
Cut the dividend in order to preserve cash to make acquisitions even though their balance sheets is fortress like. Lipitor is coming off patent in a couple of years. Stock has been very disappointing. A "show me" stock.
Photo of Gavin GrahamGavin Graham
Owned
Unlock Rating
$14.58

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Feb 09, 2009
(Market Call Minute.) Just completing an acquisition.
Photo of Brett HrybBrett HrybUnlock Rating
$14.71

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Feb 06, 2009
At this price it is probably near a low. Made a big acquisition that is scaring everybody. Can't see a lot of downside from here.
Photo of Charles BobrinskoyCharles Bobrinskoy
No
Unlock Rating
$14.84

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Jan 30, 2009
Made a huge bet with their acquisition of Wyeth and the patents are running off. If it doesn't work out they are going to have some very difficult times.
Photo of David DriscollDavid Driscoll
No
Unlock Rating
$14.58

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jan 27, 2009
(A Top Pick Jan 7/08. Down 28,2%.) Likes it for its valuation and its recent acquisition of Wyeth, which gets them into biotechnology and vaccines. Cheap on an earnings basis. Over 4% dividend. In a recession, drug stocks do relatively well. Stock has been oversold.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$15.82

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Dec 30, 2008
Currently, pharmaceutical stocks are outperforming the market. A good place to hide and to make some money. Yield of 7.2%. Lots of cash.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$17.75

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Dec 16, 2008
His model price is $24.87, a 50% upside. $24 billion in cash.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$17.36

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Dec 15, 2008
Get Out! Sell. Not a fan of pharmaceuticals. Feels innovations will be in biotechnology not pharmaceuticals.
Photo of Matthew McCallMatthew McCall
No
Unlock Rating
$16.63

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TRADE

Pfizer Inc(PFE)

Dec 09, 2008
Manufactures of the drug lipidore (the most popular cholesterol drug) Their patent is running out in 2011 - 2012 and they are considering walking away and getting into cancer drugs.
Photo of Alan Kral , CFA, CICAlan Kral , CFA, CICUnlock Rating
$16.47

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Dec 01, 2008
Health care space, specifically drugs and bio pharmaceuticals is interesting but this is not one that he would Buy. Continue to have issues with drugs coming off of patents and relatively low revenue growth. Would prefer something like Gilead Sciences (GILD-Q) or a generic like Teva (TEVA-Q). This is an area where you should have some exposure.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$15.28

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Nov 14, 2008
High dividend yield. Cheap because people think there is not much in the pipeline. Lipitor will be going off patent so earnings will drop. Almost like a short-term bond in that you get cash flow from existing drugs that are pretty dependable but not much growth. Sold his holdings about 2 years ago because of lack of growth. Relatively safe but not a lot of upside.
Photo of Charles BobrinskoyCharles Bobrinskoy
No
Unlock Rating
$16.28

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Nov 12, 2008
Have a lot of cash and produce a lot of cash flow. Very high dividend. They cannot seem to get any catalyst for growth. A lot of competition from generic drug companies.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$15.83

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Oct 22, 2008
Losing Lipitor in a couple of years but thinks this is priced into the stock. They are doing cost cutting. Pipeline is a little weak. From a historic PE level and dividend it is a very attractive value. However, if the US is to regulate more and put price fixing on drugs, that would definitely be a negative.
Photo of David AbellaDavid Abella
Owned
Unlock Rating
$16.74

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 07, 2008
Interesting sock. Almost like a bond. Price assumes there will be no significant new drugs so revenue is based on existing drugs until they come off patent. No phase 2 drugs have hit over the last 2 years.
Photo of Charles BobrinskoyCharles BobrinskoyUnlock Rating
$17.65

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 16, 2008
Drugs are coming off patent and are they going to be able to replenish the pipeline? Does management have the ability to keep the cash flow chugging along? The market is telling you No. 7% yield but that there is very little else.
Photo of David DriscollDavid Driscoll
No
Unlock Rating
$17.81

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Showing 496 to 510 of 887 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

ATD.TO -0.8$85.19
1523.HK 0$
CSU.TO -20.01$3078.66
NVO 1.74$48.66
PAYC 2.08$231.7

Today's Top Picks

ODDITY T… 0$
CDI.PA-O 0$
META 11.03$570.05
MNT.TO 0.69$69.95
COPX 1.79$96.32

Popular Articles

Latest Sell Signals

ORCL 2.31$144.76
GAW-LSE 0$
BB.TO 0.17$10.79
SHOP.TO 5.21$212.84
IBM 3.15$234.19

Most Recent Experts

Jason Del Vicario

Jason Del Vicario

HollisWealth

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Rick Rule

Rick Rule

Rule Investment Media

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automatically

You may also like